GeneSegues Therapeutics, a biopharmaceutical firm specializing in the innovation of RNA and DNA-based therapeutics in cancer and infectious disease, today announced the addition of industry veteran Tom Burke to its Board of Directors.
“We are broadening the skill set of our team and are thrilled to have Tom join us. He brings strategy expertise and longtime pharmaceutical industry experience to us at a critical time when our company is showing great progress and our technology is showing great promise. We are positioned to be transformative and Tom will be a key player in our continuing that advancement,” says Laura Brod, CEO of GeneSegues.
An accomplished pharmaceutical and biopharmaceutical professional, Mr. Burke has over 30 diverse years of management experience across multiple disciplines under his belt. Prior to his current role, he led global pharmaceutical organization Upsher-Smith as its Chief Operating Officer. His many responsibilities over his tenure included corporate leadership, operations (manufacturing/supply chain), business development (M&A, licensing), portfolio management, project management, P&L, and sales and marketing. Upon leaving Upsher-Smith in 2014, he became CEO of Manresa Partners, a private healthcare-focused consulting and management firm.
“In my new role, I have the opportunity to choose the companies I work with and am pleased to have joined GeneSegues in advancing its novel technology aimed at taking on cancer as well as the multitude of other opportunities afforded by its proprietary drug delivery platform,” said Mr. Burke. ‘I look forward to working with the GeneSegues Therapeutics team going forward.”
GeneSegues is developing a novel nanoencapsulated DNA/RNA cancer therapeutic toward Phase I clinical trials, and is engaged in collaborations to further exploit its targeted nanocapsule platform. “On the heels of our increased growth and progression, the addition of Tom to GeneSegues’ Board will provide great perspective on continuing to move in the right direction,” Ms. Brod concludes.